Atrogi
- Company typePrivate
- Founded2017
- HeadquartersSolna, Sweden
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
Atrogi firmographics
Firmographics- Name
- Atrogi
- Legal name
- Atrogi AB
- Website
- https://atrogi.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Atrogi industry classification
Industry- Product category
- Metabolic Disease Therapeutics
- akta.pro primary industry
- Diabetes (General) (HLAKADAA)
Keywords
Where Atrogi is headquartered
LocationHeadquarters
- HQ city
- Solna
- HQ country
- Sweden
- HQ region
- Europe
Offices1 record
Markets served
Atrogi business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Revenue model
- Pharmaceutical Licensing and Partnerships: Pre-revenue clinical-stage biotech company. Revenue model expected to come from licensing deals and strategic partnerships with pharmaceutical companies for co-development and commercialization of drug candidates, particularly for ATR-258 in metabolic disorders and as combination therapy with GLP-1 drugs.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels6 records
Atrogi product offering
Product offeringCore offering
Atrogi is a clinical-stage biotech company developing first-in-class small-molecule GRK2-biased β2-adrenergic receptor agonists to treat type 2 diabetes, obesity, and muscle-wasting conditions. The lead candidate ATR-258 is an oral, once-daily therapy that mimics exercise effects — driving fat loss, increasing lean muscle, and improving metabolism without the cardiovascular side effects of conventional β2-agonists. The company also has a preclinical dual β2/β3 candidate (ATR-127) for obesity and a proprietary GPCR Discovery Platform with 1,000+ compounds.
Product overview
Atrogi is a phase II ready clinical-stage biotech company pioneering first-in-class treatments for metabolic disorders. The company's portfolio centers on ATR-258, a first-in-class oral GRK2-biased β2-agonist drug candidate that mimics exercise effects by promoting fat loss, muscle growth, and improved metabolism. ATR-258 has completed Phase 1 safety trials and is advancing to Phase 2 for type 2 diabetes and obesity treatment. Additionally, ATR-127 is in preclinical development as a dual β2/β3 receptor agonist for obesity. Both compounds leverage Atrogi's proprietary GPCR Discovery Platform with over 1,000 proprietary compounds designed to fine-tune β2 signaling with minimal desensitization.
Differentiator
Problem solved
Functional benefit
Products and services
- ATR-258 ATR-258 is a first-in-class oral GRK2-biased β2-adrenergic receptor agonist designed to mimic exercise effects by driving fat loss, increasing muscle mass, and improving metabolism. It targets type 2 diabetes and obesity — including as a combination partner with GLP-1 receptor agonists to counter GLP-1-induced muscle loss — and is a once-daily oral therapy that avoids the cardiovascular side effects of conventional β2-agonists. ATR-258 has completed Phase 1 trials and is Phase II-ready.
- ATR-127 ATR-127 is Atrogi's preclinical, next-generation dual β2/β3 adrenergic receptor agonist for obesity treatment. It enables precision modulation of downstream β2 and β3 signaling cascades to boost metabolism while preserving lean body mass and reducing hepatic inflammation, with IND-enabling studies planned.
Quantifiable outcome
- Phase 1 trial: ATR-258 demonstrated safety and tolerability in 69 subjects (48 healthy volunteers + 24 type 2 diabetes patients)
- +2 more outcomes
Companies that use Atrogi
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles1 record
Atrogi technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Atrogi partnerships and signals
Strategic signalPartnerships
Eleven partnerships are on record, tiered core and minor.
- Stockholm UniversitycoreLong-term academic collaboration for research on β2-adrenergic receptor signaling. Co-authors from Stockholm University contributed to the landmark Cell publication. Part of Eurostars grant consortium for obesity project.
- University of CopenhagencoreClinical trial partnership led by Associate Professor Morten Hostrup, a leading authority on β2-adrenergic receptor signaling in skeletal muscle. Professor Hostrup sponsors and leads the 8-week human trial for ATR-258 evaluating muscle physiological effects.
- Karolinska InstitutetcoreAcademic collaboration including Assistant Professor Shane Wright who co-elucidated the GRK2-biased mechanism underpinning ATR-258's muscle-specific effects. Contributed to Cell publication alongside Atrogi scientists.
- University of NottinghamcoreAcademic collaborator on the Cell publication research. Part of international collaboration involving multiple leading European and Australian institutions.
- Monash UniversitycoreAcademic collaborator on the GRK-biased adrenergic agonists research. Contributed to Cell publication alongside Atrogi and other international institutions.
- University of QueenslandcoreInternational academic collaborator on the Cell publication research, part of the multi-institutional effort validating Atrogi's GRK2-biased signaling approach.
- Clinical Research Services (CRS)coreContract research organization that conducted the Phase 1a/b clinical trial for ATR-258 in Mannheim, Germany. The double-blind, placebo-controlled, randomized study evaluated safety in healthy volunteers and type 2 diabetes patients.
- Eurostars ConsortiumminorEurostars grant consortium including Stockholm University, Maastricht University, Latvian Institute of Organic Synthesis, and Excellerate Bioscience. Awarded approximately EUR 1 million for obesity project development, ranked 31 out of 449 applications.
- Maastricht UniversityminorPart of Eurostars grant consortium for obesity project, collaborating with Atrogi on development of novel obesity treatment.
- Latvian Institute of Organic SynthesisminorPart of Eurostars grant consortium for obesity project, contributing to the international collaboration on novel anti-obesity compounds.
- Excellerate BioscienceminorPart of Eurostars grant consortium for obesity project, contributing to development efforts alongside academic partners.
Scale indicators8 records
Recent moves6 records
Expansion highlights6 records
Atrogi competitors and assessment
Company assessmentDirect peers
- BioAge Labs: Clinical-stage biotech developing drugs for metabolic diseases of aging, with lead programs in obesity and muscle preservation. Comparable to Atrogi as a small-cap clinical biotech pursuing novel mechanisms for muscle-sparing weight loss in the GLP-1 era.
- Rivus Pharmaceuticals: Clinical-stage biotech developing HU6, a controlled metabolic accelerator for obesity and cardiometabolic disease. Directly comparable to Atrogi in targeting metabolic disease with first-in-class small molecules and pursuing muscle-preserving mechanisms.
- Structure Therapeutics: Clinical-stage biotech developing oral small molecule GLP-1 agonists for obesity and T2D. Comparable as a small-cap clinical biotech targeting the same metabolic indications with novel oral mechanisms versus injectable incumbents.
- Zealand Pharma: Clinical and commercial-stage Danish biotech focused on metabolic diseases including obesity and diabetes. Comparable therapeutic focus and small-molecule approach to metabolic disorders, though at a more advanced stage.
- Terns Pharmaceuticals: Clinical-stage biotech developing small molecules for obesity and MASH/NASH, with lead candidate TERN-501 (THR-β agonist). Comparable as a small-molecule developer pursuing differentiated mechanisms in the cardiometabolic space.
- Biomea Fusion: Clinical-stage biotech developing menin inhibitors for type 2 diabetes and oncology. Comparable as a small-cap clinical biotech pursuing novel diabetes mechanisms with potential disease-modifying positioning.
Emerging players
- Keros Therapeutics: Clinical-stage biotech developing treatments for hematological and musculoskeletal disorders with potential metabolic applications. Comparable profile as a small-cap clinical biotech with proprietary platform approach.
Broad incumbents
- Novo Nordisk: Global leader in diabetes and obesity therapeutics with the dominant GLP-1 franchise (Ozempic, Wegovy). Atrogi's ATR-258 is positioned partly as a combination partner with Novo Nordisk's GLP-1 portfolio to address muscle loss.
- Eli Lilly: Global pharma leader in diabetes and obesity with tirzepatide (Mounjaro/Zepbound) franchise. Most likely large-pharma partner for ATR-258 given Lilly's active business development in muscle-preserving obesity combinations.
- AstraZeneca: Global pharma with major diabetes franchise (dapagliflozin/Forxiga). Particularly relevant given that Atrogi's CMO led dapagliflozin development and Chairman was former AZ CEO, creating potential strategic partnership pathway.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Atrogi social profiles
Digital presenceAtrogi financial estimates
Financial estimateRevenue estimate
Valuation estimate
Atrogi leadership team
Management profileNumber of profiles
Profiles12 records
Atrogi funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Atrogi M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Atrogi
What does Atrogi do?
Atrogi is a clinical-stage biotech company developing first-in-class small-molecule GRK2-biased β2-adrenergic receptor agonists to treat type 2 diabetes, obesity, and muscle-wasting conditions. The lead candidate ATR-258 is an oral, once-daily therapy that mimics exercise effects — driving fat loss, increasing lean muscle, and improving metabolism without the cardiovascular side effects of conventional β2-agonists. The company also has a preclinical dual β2/β3 candidate (ATR-127) for obesity and a proprietary GPCR Discovery Platform with 1,000+ compounds.
Is Atrogi a public or private company?
Atrogi is a private company. It is classified as venture growth investor backed and is currently operating.
When was Atrogi founded?
Atrogi was founded in 2017. It employs 1 to 10 people.
Where is Atrogi based?
Atrogi is headquartered in Solna, Sweden, in the Europe region.
How does Atrogi make money?
One revenue line is on record: pharmaceutical Licensing and Partnerships.
Who are Atrogi's main competitors?
Direct peers on record are BioAge Labs, Rivus Pharmaceuticals, Structure Therapeutics, Zealand Pharma, Terns Pharmaceuticals and Biomea Fusion. Keros Therapeutics is listed as an emerging player. Broad incumbents are Novo Nordisk, Eli Lilly and AstraZeneca.
Does Atrogi have an API?
No public API is recorded for Atrogi.
What industry is Atrogi in?
Atrogi's product category is Metabolic Disease Therapeutics. Its primary akta.pro industry code is HLAKADAA, Diabetes (General).